Assessment of Pharmacokinetics and Food Effect of AD‐109, a Novel Formulation of Rivaroxaban 18 mg
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70439 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Hyunwook Ryu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Rivaroxaban, Food-Drug Interactions, Factor Xa Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Addpharma Co. Ltd., Yuhan Corporation, Ministry of Trade Industry & Energy (MOTIE, Korea).
Abstract (Originalsprache)
Rivaroxaban is an oral anticoagulant that requires food intake at high doses (15 and 20 mg) due to a pronounced food effect. AD‐109 is a novel formulation of rivaroxaban 18 mg, designed to enhance oral bioavailability and mitigate the food effect. This study aimed to evaluate the pharmacokinetics (PKs) of AD‐109 compared to the conventional formulation, Xarelto (Xarelto, rivaroxaban 20 mg) and the effect of food on the PK of AD‐109. Two open‐label, single‐dose, two‐period, two‐sequence crossover studies were conducted. In Study 1, participants received a single dose of AD‐109 and Xarelto under fed state, while in Study 2, participants received a single dose of AD‐109 under fed and fasted state. Serial blood samples were collected up to 34 h post‐dose and PK parameters were calculated by non‐compartmental method. In both studies, 33 out of 36 volunteers completed the study. The geometric mean ratios (GMRs) and their 90% confidence intervals (CIs) for the maximum plasma concentration ( C max ) and area under the curve until the last measurable concentration (AUC 0‐last ) of rivaroxaban for AD‐109 to Xarelto were 1.0466 (0.9961–1.0996) and 0.9450 (0.9094–0.9819), falling within the bioequivalence range of 0.8–1.25. The corresponding values of AD‐109 in the fed to fasted state were 1.0475 (0.9789–1.1209) and 0.9795 (0.9371–1.0238), suggesting the systemic exposure was not substantially influenced by food intake. AD‐109 (rivaroxaban 18 mg) demonstrated a PK profile comparable to that of Xarelto (rivaroxaban 20 mg) and effectively minimized the food effect on drug exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Addpharma Co., Ltd, Seongnam-si, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Joo-Youn Cho, SeungHwan Lee
Förderung
- Addpharma Co. Ltd.
- Yuhan Corporation
- Ministry of Trade Industry & Energy (MOTIE, Korea)
- Yuhan
Zitieren
APA
Ryu, H., Cho, J. Y., Lee, T., Kim, J., & Lee, S. (2025). Assessment of Pharmacokinetics and Food Effect of AD‐109, a Novel Formulation of Rivaroxaban 18 mg. Clinical and Translational Science. https://doi.org/10.1111/cts.70439
Vancouver
Ryu H, Cho JY, Lee T, Kim J, Lee S. Assessment of Pharmacokinetics and Food Effect of AD‐109, a Novel Formulation of Rivaroxaban 18 mg. Clinical and Translational Science. 2025. doi:10.1111/cts.70439
BibTeX
@article{Ryu2025,
author = {Ryu, Hyunwook and Cho, Joo-Youn and Lee, Taewon and Kim, Jandee and Lee, SeungHwan},
title = {Assessment of Pharmacokinetics and Food Effect of AD‐109, a Novel Formulation of Rivaroxaban 18 mg},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70439}
}
EUVIMED